Velox Design Lab · Shared design

Triple-incretin triad

Research target: A GLP-1 / GIP / glucagon triple receptor agonist, optimised for synthesisability and a longer plasma half-life.
Tri-Inc α
91
✦ Likely brand-new
HAEGTFTSDYSKYLD

An incretin-style backbone tuned to be shorter and easier to make than full-length agonists.

Tri-Inc β
83
✦ Likely brand-new
YAEGTFISDYSIALD

A sister design swapping a couple of residues to probe receptor selectivity.

GlucaFuse
92
✦ Likely brand-new
HSQGTFTSDYSKYLDE

A glucagon-leaning candidate with an added acidic tail for stability.

Design your own novel peptide free →
Closest compound you can order today
Retatrutide
This brief points straight at Retatrutide — the closest characterised compound Velox stocks for this kind of research.
Designed sequences are novel hypotheses that still have to be synthesised. Retatrutide is real material you can study now — ≥99% HPLC-verified, batch Certificate of Analysis included, dispatched from the UK the next working day.
Research Retatrutide →Browse related compounds →
Velox Design Lab outputs are computational sequence predictions for in vitro research use only. They are hypotheses, not validated compounds, and are not a medicinal product, not medical advice, and not for human or veterinary use. See our Research Use Policy.
Velox Design Lab outputs are computational predictions for in vitro research use only. Not validated compounds; not for human or veterinary use.
CRP Labs Ltd · NI738125 · About Design Lab · Research Use Policy